Connect with us

Technology

AI-Driven Market Transformation, Europe’s Pharma E-Commerce to Grow by USD 38.7 Billion from 2024-2028, Boosted by Internet Accessibility

Published

on

NEW YORK, Oct. 1, 2024 /PRNewswire/ — Report with the AI impact on market trends- The global pharma e-commerce market in Europe size is estimated to grow by USD 38.7 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 16.27%  during the forecast period. Availability of internet provides convenience to consumers is driving market growth, with a trend towards growing acceptance in newly regulated european states. However, illegal and counterfeit trading of drugs through e-pharmacy  poses a challenge. Key market players include Ace Chemist Direct, apo rot GmbH, Apotea AB, Arzneiprivat, Atropa Pharmacy, Chemist4U Innox Trading Ltd., Dirk Rossmann GmbH, DocMorris AG, EURO PHARM International Canada Inc., Farmacia Campoamor, Juvalis, McKesson Corp., myCARE e.k, Parafarmacia online, Pharmacy2U Ltd., Redcare Pharmacy, The French Pharmacy, UK MEDS Direct Ltd., Walgreens Boots Alliance Inc., and Wort and Bild Verlag Konradshohe GmbH and Co. KG.

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report

Pharma E-Commerce Market In Europe Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 16.27%

Market growth 2024-2028

USD 38.7 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

15.12

Regional analysis

Europe

Performing market contribution

Europe at 100%

Key countries

Germany, UK, France, Italy, and Rest of Europe

Key companies profiled

Ace Chemist Direct, apo rot GmbH, Apotea AB, Arzneiprivat, Atropa Pharmacy, Chemist4U Innox Trading Ltd., Dirk Rossmann GmbH, DocMorris AG, EURO PHARM International Canada Inc., Farmacia Campoamor, Juvalis, McKesson Corp., myCARE e.k, Parafarmacia online, Pharmacy2U Ltd., Redcare Pharmacy, The French Pharmacy, UK MEDS Direct Ltd., Walgreens Boots Alliance Inc., and Wort and Bild Verlag Konradshohe GmbH and Co. KG

Market Driver

Pharma e-commerce in Europe is witnessing significant growth due to the increasing demand for personalized medicine and health solutions. Leveraging data analytics and artificial intelligence, these platforms provide customized recommendations, treatment plans, and wellness programs based on individual preferences and health histories. Personalized medicine, which involves customizing medical treatment to each patient’s unique characteristics, is facilitated through a wide range of offerings, including specialty drugs and compounded medications. Patients can work with healthcare professionals to develop personalized treatment regimens and order necessary medications online. The trend extends beyond disease treatment to encompass wellness and preventive care, with e-commerce platforms offering health supplements, vitamins, and wellness products tailored to individual health goals. The European pharma e-commerce market is expected to grow, fueled by this trend and the innovation it inspires, including genetic testing services and health monitoring devices.

The European pharma e-commerce market is experiencing significant growth, with medications, medical supplies, and healthcare products leading the way. Remote healthcare services, such as telemedicine and e-prescriptions, are also trending, especially among the elderly population with chronic diseases. Consumer convenience and cost-effective solutions are key drivers, with many opting for online pharmacies and mail-order services. However, challenges persist, including counterfeit pharmaceuticals, data protection, and consumer trust. Healthcare systems and internet connectivity are essential for the success of digital healthcare solutions. Omnichannel retailing, including inventory data and logistics, is crucial for supply chain efficiency. Direct sales to healthcare professionals are also increasing. E-prescriptions and digital prescription services are becoming more common, but illegal and unregulated online pharmacies pose a threat to consumer safety. Quality assurance and regulatory compliance are essential to maintain consumer trust.

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

The proliferation of counterfeit drugs in the European pharma e-commerce market poses a significant challenge. These drugs, sold through virtual platforms, undermine industry integrity and pose health risks due to incorrect ingredients or dosages. Illicit drugs such as cannabis, heroin, and cocaine are commonly traded. This globalized counterfeit drug trade increases societal threats, including drug-related crimes and fatalities from overdoses. E-commerce’s lack of regulation and oversight enables third-party sellers to exploit loopholes, making it difficult for authorities to monitor and control sales effectively. This situation negatively impacts the growth of the pharma e-commerce market in Europe, potentially hindering its forecasted expansion.The European pharma e-commerce market is experiencing significant growth due to an aging population and the rise of online and mail-order pharmacies. Challenges include managing chronic diseases, ensuring patient safety, and addressing illegal and unregulated online pharmacies. Digital prescription services and e-prescriptions are key trends, but logistics and inventory data management are crucial for success. Omnichannel retailing, including OTC medications and prescription medications, targets a large patient population. Health insurers and digital healthcare platforms are driving demand for electronic prescriptions and mobile applications. AI chatbots and machine learning enable personalized patient care, while data analytics and prescription refills enhance convenience. Cross-border e-commerce and drug counterfeiting pose risks, requiring strict regulation and biometric identification for security. The diabetes segment and immune-system diseases are major growth areas in the B2C market. Manufacturer-owned marketplaces and digital technologies are transforming the industry, offering new opportunities for growth.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview 

This pharma e-commerce market in Europe report extensively covers market segmentation by

Product 1.1 Medications1.2 Health/wellness and nutrition1.3 Personal care and essentialsType 2.1 Rx2.2 OTCGeography 3.1 Europe

1.1 Medications-  The European pharma e-commerce market is experiencing significant growth due to the increasing demand for medications as the population ages and the prevalence of chronic diseases rises. Online pharmacies offer consumers the convenience of purchasing essential medications without visiting physical pharmacies, making it an attractive option for individuals with mobility issues, busy lifestyles, or those living in remote areas. These platforms provide access to a wide range of medications, including specialty drugs and rare medications, ensuring consumers have access to the necessary treatments regardless of their location. Additionally, online platforms offer valuable information on medication side effects, low-cost substitutes, and potential drug interactions, enabling consumers to make informed purchasing decisions. These factors contribute to the anticipated growth of the medications segment and the pharma e-commerce market in Europe during the forecast period.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

Pharma e-commerce in Europe is experiencing significant growth, driven by the increasing elderly population and the demand for convenient healthcare solutions. Online pharmacies and mail-order pharmacies are becoming popular, offering prescription medications, over-the-counter pharmaceuticals, and healthcare products. Telemedicine and digital prescription services enable remote healthcare consultations and electronic prescriptions. However, the rise of illegal online pharmacies poses a threat, selling counterfeit pharmaceuticals and compromising data protection. Two-factor authentication and data analytics help ensure security and personalized services. Mobile applications facilitate prescription refills and remote healthcare services. Artificial intelligence and data analytics improve patient care and optimize supply chain management. Overall, pharma e-commerce in Europe offers a wide range of digital platforms for medications, medical supplies, and healthcare products, enhancing consumer convenience and accessibility for chronic disease management and life expectancy improvement.

Market Research Overview

The Pharma E-Commerce Market in Europe is experiencing significant growth due to the increasing elderly population, chronic diseases, and advancements in digital healthcare. Online pharmacies and mail-order pharmacies are becoming increasingly popular, offering convenience and accessibility to patients. Telemedicine and e-prescriptions are also on the rise, enabling remote healthcare services and digital prescription services. However, the market also faces challenges such as illegal and unregulated online pharmacies, drug counterfeiting, and healthcare accessibility issues. Healthcare professionals, health insurers, and manufacturer-owned marketplaces are also playing key roles in this evolving landscape. Omnichannel retailing, inventory data management, logistics, and cost-effective solutions are essential for success in this market. Digital technologies, including AI chatbots, machine learning, and data analytics, are transforming the industry, offering personalized healthcare and consumer convenience. E-commerce platforms, mobile applications, prescription refills, and two-factor authentication are also driving growth in the B2C segment. Data protection and quality assurance are crucial for consumer trust, while cross-border e-commerce and medical tourism are expanding opportunities for growth. The market for prescription medications, OTC medications, medical supplies, and healthcare products is expected to continue growing, fueled by increasing healthcare expenses, internet penetration, and the need for cost-effective solutions.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ProductMedicationsHealth/wellness And NutritionPersonal Care And EssentialsTypeRxOTCGeographyEurope

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-driven-market-transformation-europes-pharma-e-commerce-to-grow-by-usd-38-7-billion-from-2024-2028–boosted-by-internet-accessibility-302262479.html

SOURCE Technavio

Continue Reading

Technology

Chemours Announces Dates for Third Quarter 2026 Earnings Release and Webcast Conference Call

Published

on

By

WILMINGTON, Del., Oct. 21, 2026 /PRNewswire/ — The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) today announced that the Company expects to issue its third quarter 2026 financial results after market on Monday, November 2, 2026.

The Company expects to hold its conference call to discuss its third quarter 2026 financial results at 8:00 a.m. Eastern Standard Time on Tuesday, November 3, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the “Events and Presentations” section of the Investor Relations section of Chemours’ website at investors.chemours.com.

Conference Call: Please visit investors.chemours.com for a link to the live webcast and to view the accompanying slides.

Replay: A webcast replay will be available at investors.chemours.com.

About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers’ biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn. 

CONTACTS:

INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3300 
investor@chemours.com 

NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/chemours-announces-dates-for-third-quarter-2026-earnings-release-and-webcast-conference-call-302915935.html

SOURCE The Chemours Company

Continue Reading

Technology

AGEDB Announces Preliminary Technical Evaluation of Graph Database and AI Data Platform Opportunities

Published

on

By

VANCOUVER, BC, Oct. 21, 2026 /CNW/ — AGEDB Technology Ltd. (TSXV: AGET) (“AGEDB” or the “Company”) announces that it is evaluating opportunities to re-engage in its historical graph database business area through preliminary architectural design and technical assessment of potential AI data platform applications, following its entry, on September 16, 2026, into a memorandum of understanding (the “MOU”) with a Korea-listed company exploring opportunities to enter the AI sector (the “Korean Company”).

The Company previously disclosed that it had discontinued its graph database management system operations during the year ended April 30, 2025 and was seeking new business opportunities. The Company is now assessing potential opportunities to leverage its existing Apache AGE-related technology and experience. These preliminary evaluations should not be interpreted as a resumption of full-scale development or commercial operations.

Under the MOU, AGEDB and the Korean Company contemplate evaluating an integrated package combining locally installed PostgreSQL and Apache AGE relationship-analysis database technology with an AI agent. The MOU also contemplates a separate “Personal AI Operating System” evaluation track, referred to as “AGE Brain,” for potential use in user-controlled computing environments. The proposed applications remain conceptual and subject to further technical and commercial assessment.

The contemplated preliminary work includes architectural design and technical evaluation of approaches to connecting relational data with graph-based relationships and supporting AI-assisted information retrieval and analysis. The parties may consider proof-of-concept testing and pilot activities, but no timeline or commitment to undertake such activities has been established under the MOU.

The MOU has a one-year term. Except for provisions expressly identified as binding, it is non-binding and does not require either party to complete development, launch or commercialize a product, make an investment, commit personnel, pay development fees, or enter into a definitive commercial agreement. Specific project scope, deliverables, schedules, responsibilities, costs and any commercialization terms remain subject to further discussions and, where applicable, separate written agreements. Each party will bear its own evaluation costs unless otherwise agreed in writing.

The Company’s evaluation remains preliminary. No product launch, commercial revenue or definitive commercialization arrangement has been agreed, and there can be no assurance that the parties will proceed with development, that the proposed platform will be completed or commercialized, or that the Company will obtain the resources required to advance the opportunity.

AGEDB may also explore potential collaborations with AI development companies in Korea and other markets, subject to available resources and further assessment.

AGEDB Technology Ltd.

On behalf of the board of directors,

“Jungsoo Kim”
CEO

About AGEDB Technology Ltd.

AGEDB Technology Ltd. is a technology company listed on the TSX Venture Exchange under the symbol “AGET.” The Company is focused on developing and pursuing opportunities in data intelligence, graph database technology and applied artificial intelligence.

Forward-Looking Information

This news release contains forward-looking information, including statements regarding the Company’s development activities, the proposed AI data platform, potential proof-of-concept and pilot activities, and possible future collaborations and commercialization. Forward-looking information is based on management’s current expectations and assumptions and is subject to risks and uncertainties that could cause actual results to differ materially. The memorandum of understanding is generally non-binding, and there can be no assurance that the parties will proceed with or complete any development, pilot, product launch or commercial arrangement, or that AGEDB will enter into additional collaborations. Readers are cautioned not to place undue reliance on forward-looking information. AGEDB undertakes no obligation to update such information except as required by applicable securities laws.

SOURCE AGEDB Technology Ltd.

Continue Reading

Technology

Bose Corporation Acquires Skullcandy, Expanding Its Consumer Audio Portfolio to Reach New Audiences

Published

on

By

Acquisition follows a successful partnership between the two companies and advances Bose’s evolution into a multi-brand products and technology company

FRAMINGHAM, Mass. and PARK CITY, Utah, Oct. 21, 2026 /PRNewswire/ — Bose Corporation, a global leader in audio innovation and research, announced today it has acquired Skullcandy, a lifestyle audio brand known for its bold products that bring together sound, style and performance. Bose and Skullcandy have each spent decades finding new ways to bring people closer to the music they love. Together, they’ll combine Bose’s audio expertise, technology and global reach with Skullcandy’s design, understanding of its consumers and authentic community connections to create new products and experiences and accelerate growth.

The acquisition follows a multi-year partnership that has already brought Sound by Bose technology to Skullcandy earbuds and headphones. The companies have seen firsthand how their strengths can come together to create products consumers love while staying true to what makes Skullcandy special, providing a foundation to accelerate further collaboration and innovation.

With a strong position at the intersection of audio, lifestyle and culture, Skullcandy will remain a separate brand within Bose’s Premium Consumer Audio business. Skullcandy’s deep roots in boardsports, including longstanding relationships with passionate supporters of the culture and its athletes, and authentic connections across music, gaming, fitness and other communities present new ways for Bose to meaningfully connect with consumers where it has less presence today.

“For more than 60 years, Bose has been committed to delivering incredible audio experiences however and wherever people choose to listen. As we work to reach even more people, we’re expanding how we do that, not only through Bose products, but through technology partnerships and a growing portfolio of brands,” said Lila Snyder, Chief Executive Officer of Bose Corporation. “As a privately held company, we have the freedom to make bold, long-term investments in opportunities we believe in, and Skullcandy is a great example of that. They have an established, thriving brand, and together we see tremendous opportunity to create new products and experiences and reach more consumers around the world.”

“We believe this is a win for Skullcandy and our fans,” said Brian Garofalow, Chief Executive Officer of Skullcandy. “Skullcandy was born on a chairlift in Park City, Utah, over 20 years ago, and we’ve always believed great music should be part of the experiences people love. Joining Bose gives us the opportunity to make those experiences even better by bringing more of their audio expertise and technology to our products, and it opens up even more ways to take Skullcandy further.”

Bose plans to invest in Skullcandy’s continued growth, providing greater access to technology, resources, global distribution and commercial relationships while giving the brand the freedom to continue evolving in ways that are authentic to its identity and consumers. Skullcandy will continue to be based in Park City, Utah.

Bose acquired Skullcandy from a fund managed by Mill Road Capital Management LLC, a Connecticut-based private investment firm. Jones Day acted as Bose’s legal counsel. Additional information, including financial and other terms of the transaction, will remain confidential.

About Bose Corporation
Bose Corporation is a global leader in audio innovation, driven by a singular belief: sound has the power to transform the way people connect with the world. For more than 60 years, Bose has combined pioneering research, engineering excellence, and a deep understanding of human perception to create products and technologies that deliver extraordinary experiences. Through its portfolio of iconic brands, including Bose, McIntosh, Sonus faber, and Skullcandy, the company offers premium and luxury audio solutions for the home, on the go, and in the car. Bose also collaborates with leading companies across industries, extending its audio expertise and technologies into new products, platforms, and applications beyond its own brands. 

Guided by a relentless spirit of innovation and a passion for what sound makes possible, Bose continues to advance the science and art of sound while expanding its impact on everyday life. From music and entertainment to communication, wellness, and emerging applications, Bose is creating new ways for people around the world to feel more connected, inspired, and engaged through the power of sound.

About Skullcandy
Founded in 2003 on a chairlift in Park City, Utah, Skullcandy is the original lifestyle audio brand. With deep roots in action sports culture, Skullcandy creates headphones, earbuds, and speakers that deliver powerful sound, bold style, and immersive experiences. Designed to move with you—from the mountains to the streets—Skullcandy gear is built to perform and made to stand out. Learn more at www.Skullcandy.com.

Contact

Joanne Berthaume
Joanne_berthaume@bose.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bose-corporation-acquires-skullcandy-expanding-its-consumer-audio-portfolio-to-reach-new-audiences-302915875.html

SOURCE Bose Corporation

Continue Reading

Trending